Information to Patients
Please find all related articles below.
Brussels, 17 May – In a seminar hosted yesterday by the Group of the Progressive Alliance of Socialists & Democrats (S&D) in the European Parliament and the Member of the European Parliament (MEP) Alejandro Cercas (S&D, Spain), six MEPs from various political groups (1) along with representatives of governments, leading academics, researches and public health organisations (2) met to raise awareness about one of the most alarming issues that European healthcare systems (...)
This high level meeting revolved around various political processes linked to the economic crisis. Some of the topics discussed include implementation of the Europe 2020 strategy, as well as pharmaceutical legislation for ensuring that people living in Europe have access to a wide range of quality and affordable medicines.
The meeting hosted by Mr Alejandro Cercas, MEP (Spain,S&D) and by the Socialists and Democrats in the European Parliament (S&D Group) served to assess the impact (...)
As one of the deliverables of the pharmacovigilance legislation, that came into effect in July 2012, the European Medicines Agency (EMA) released an initial list of drugs subject to additional monitoring on 25 April 2013.
Please click here to read the full EMA Press Release, which contains additional information.
How to identify them?
Medicines subject to additional monitoring will have to display an inverted back triangle in their package leaflet and in the information for healthcare (...)
On 21 February 2013, EPHA attended the European Pharmaceutical Students Association (EPSA) Annual Reception at the European Parliament, entitled “Health Inequalities – Access to Medicines”. The event was hosted by MEP Elena Oana ANTONESCU (Romania, EPP) and MEP Marisa Matias (Portugal, GUE/NGL).
The EPSA reception brought together experts from the pharmaceutical arena, health professionals, as well as patients associations. The following speakers took part in the panel: (...)
In recent years the Lancet, a world-class medical journal, has drawn attention to important developments in health and health policy taking place in parts of the world that would otherwise risk being overlooked, publishing a series of articles that examine, in depth, what is happening in countries such as China, Mexico, Brazil and Japan. Now, it is coming home.
Looking at what is happening on its own doorstep, in the continent of Europe, a series of articles will be undertaken in (...)
On 30 of November, EPHA attended the roundtable on “eHealth solutions – Additional cost burden or efficiency factor for Europe’s health systems?” Aimed to discuss the economic rationale for using eHealth solutions, the event was organised by the European Policy Centre (EPC).
The event brought together experts to discuss questions around eHealth and the sustaibility of health systems: . To what extent can eHealth improve the sustainability of Europe’s health (...)
The number of reports of medicine shortages in the EU is increasing. Shortages are occurring across the supply chain and all classes of medicines are affected, from complex chemotherapy agents and anaesthetics to diabetes, hypertension, and asthma medication.
This article is a contribution by the Pharmaceutical Group of the European Union (PGEU)
There are a number of reasons why some medicines are sometimes unavailable. The medicines supply chain is highly complex and its efficiency (...)
The European Commission has requested that the European Medicines Agency (EMA) should investigate the company Roche Registration Ltd. for allegedly failing to comply with Pharmacovigilance requirements in relation to its 19 centrally- authorised medicines. EMA stated that it has started an infringement procedure against the company.
On the basis of the infringement procedures, a pharmacovigilance inspection was carried out by the UK Medicines and Healthcare Products Regulatory Agency (...)
In light of the recent PIP breast implant scandal, more monitoring of certification bodies is requested under the new proposed Medical Devices Directive to improve patient safety.
Until now, independent certification bodies, approved by Member States, provided authorisation to medical devices coming into the market.
Some MEPs are calling for a centralised EU authorisation of medical devices, however the Commission will not propose this for the Medical Devices Directive (MDD). Eucomed, (...)